Selected article for: "neutralization potency and potency breadth"
Author: Brian G. Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A. Toth; Richard A. Urbanowicz; Johnathan D. Guest; Pragati Agnihotri; Melissa C. Kerzic; Alexander Marin; Alexander K. Andrianov; Jonathan K. Ball; Roy A. Mariuzza; Thomas R. Fuerst; Steven K.H. Foung
Title: Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization
  • Document date: 2020_4_17
    • ID: b6to1v4u_5
    Snippet: There have been a number of successful structure-based vaccine designs for variable viruses such as influenza (12, 13) , HIV (14, 15) , and RSV (16, 17) where rationally designed immunogens optimize presentation of key conserved epitopes, mask sites using N-glycans, or stabilize conformations or assembly of the envelope glycoproteins. Recent studies have reported use of several of these strategies in the context of HCV glycoproteins, including re.....
    Document: There have been a number of successful structure-based vaccine designs for variable viruses such as influenza (12, 13) , HIV (14, 15) , and RSV (16, 17) where rationally designed immunogens optimize presentation of key conserved epitopes, mask sites using N-glycans, or stabilize conformations or assembly of the envelope glycoproteins. Recent studies have reported use of several of these strategies in the context of HCV glycoproteins, including removal or modification of N-glycans to improve epitope accessibility (18, 19) , removal of hypervariable regions (18, 20, 21) , or presentation of key conserved epitopes on scaffolds (22, 23) . However, such studies have been relatively limited compared with other viruses, in terms of design strategies employed and number of designs tested, and immunogenicity studies have not shown convincing improvement of glycoprotein designs over native glycoproteins in terms of neutralization potency or breadth (18, 21) , with the possible exception of an HVR-deleted high molecular weight form of the E2 glycoprotein that was tested in guinea pigs (20) .

    Search related documents:
    Co phrase search for related documents
    • assembly conformation and guinea pig: 1
    • breadth neutralization potency and envelope glycoprotein: 1
    • breadth neutralization potency and neutralization potency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • breadth neutralization potency and vaccine design: 1, 2
    • conserve epitope and envelope glycoprotein: 1
    • conserve epitope and vaccine design: 1
    • design strategy and envelope glycoprotein: 1
    • design strategy and glycoprotein design: 1, 2
    • design strategy and neutralization potency: 1, 2
    • design strategy and rationally design: 1
    • design strategy and recent study: 1
    • design strategy and test design: 1, 2, 3
    • design strategy and vaccine design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38